Published in Cancer Weekly, September 16th, 2003
According to recent research from Hungary, "Tumor necrosis factor (TNF)-alpha producing tumors as vaccines were demonstrated to induce a therapeutic anti-tumor immune response, but their clinical use is limited by the toxicity of soluble TNF. We investigated the growth characteristics and immunomodulatory properties of HeLa cells producing an uncleavable transmembrane form of TNF (preTNF)."
"The growth of the transformed tumors was compromised in both immunosuppressed and severe combined...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-09-16)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.